Download our whitepaper,
Multiple Sclerosis Trials: Disease
Modulation and Therapeutic
Innovations
What's Inside:
- Epidemiology and subtypes of multiple sclerosis.
- MRI biomarkers and lesion activity monitoring.
- Relapse rate and disability progression endpoints.
- Immunomodulatory and neuroprotective treatment approaches.
- Real-world data and long-term safety assessment.
- Challenges in progressive MS trial designs.
Access your complimentary whitepaper today:
Multiple Sclerosis Clinical Trials
Multiple Sclerosis (MS) is a complex, chronic disease affecting the central nervous system, which includes the brain, spinal cord, and optic nerves. It is characterized by the immune system mistakenly attacking the protective sheath (myelin) that covers nerve fibers, causing communication problems between the brain and the rest of the body. Eventually, the disease can cause permanent damage or deterioration of the nerves.
Over the years, advancements in research have led to a better understanding of the pathophysiological mechanisms of MS, allowing for more targeted therapeutic approaches. The evolution of treatment strategies from broad immunosuppressive therapies to more specific immunomodulatory drugs reflects the growing understanding of the disease’s complex nature.
iNGENū’s team of researchers and clinicians is dedicated to advancing Multiple Sclerosis research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Multiple Sclerosis.
2.8M
people worldwide are affected by MS
2x
Women are about twice as likely as men to be diagnosed with MS
20-40
The onset of MS symptoms often occurs in young adulthood, typically between the ages of 20 and 40
Our clinical team has over
120
years of combined clinical trial experience